Consistent with our company’s vision, mission, and values, we are committed to pursuing sustainability initiatives that are an integral part of our business and go beyond economic, legal, or regulatory motives. At Frontage, we have implemented a sustainability framework that promotes long-lasting values for our people, customers, and all stakeholders.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage is a CRO providing integrated, scientifically-driven research, analytical and product development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals.
We offer our clients comprehensive services in analytical testing and formulation development, drug metabolism and pharmacokinetics (DMPK), bioanalysis, preclinical safety and toxicology and early phase clinical studies. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients.
We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance.
Frontage Laboratories, Inc. is a full-service CRO providing integrated, scientifically-driven research, analytical and development services. With over 20 years of experience, we have successfully assisted our clients in advancing hundreds of compounds through the drug development process.
Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.